Skip to main content
. 2023 Jun 15;24(6):953–961. doi: 10.1007/s40257-023-00798-0

Fig. 1.

Fig. 1

Percentages of upadacitinib-treated patients achieving Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 responses through 48 weeks of treatment